- Home
- AMZE vs QNTM Comparison
AMZE vs QNTM Comparison
Compare AMZE & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMZE
- QNTM
- Stock Information
- Founded
- AMZE 2019
- QNTM 1998
- Country
- AMZE United States
- QNTM Canada
- Employees
- AMZE N/A
- QNTM N/A
- Industry
- AMZE Beverages (Production/Distribution)
- QNTM
- Sector
- AMZE Consumer Staples
- QNTM
- Exchange
- AMZE Nasdaq
- QNTM NYSE
- Market Cap
- AMZE 6.5M
- QNTM 35.6M
- IPO Year
- AMZE 2021
- QNTM N/A
- Fundamental
- Price
- AMZE $0.36
- QNTM $13.46
- Analyst Decision
- AMZE
- QNTM
- Analyst Count
- AMZE 0
- QNTM 0
- Target Price
- AMZE N/A
- QNTM N/A
- AVG Volume (30 Days)
- AMZE 94.0K
- QNTM 210.7K
- Earning Date
- AMZE 05-20-2025
- QNTM 05-14-2025
- Dividend Yield
- AMZE N/A
- QNTM N/A
- EPS Growth
- AMZE N/A
- QNTM N/A
- EPS
- AMZE N/A
- QNTM N/A
- Revenue
- AMZE $254,711.00
- QNTM N/A
- Revenue This Year
- AMZE N/A
- QNTM N/A
- Revenue Next Year
- AMZE N/A
- QNTM N/A
- P/E Ratio
- AMZE N/A
- QNTM N/A
- Revenue Growth
- AMZE N/A
- QNTM N/A
- 52 Week Low
- AMZE $0.25
- QNTM $2.70
- 52 Week High
- AMZE $1.25
- QNTM $23.81
- Technical
- Relative Strength Index (RSI)
- AMZE N/A
- QNTM 73.02
- Support Level
- AMZE N/A
- QNTM $10.75
- Resistance Level
- AMZE N/A
- QNTM $13.44
- Average True Range (ATR)
- AMZE 0.00
- QNTM 1.39
- MACD
- AMZE 0.00
- QNTM 0.22
- Stochastic Oscillator
- AMZE 0.00
- QNTM 83.46
About AMZE Amaze Holdings Inc. Common Stock
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.